Fluoroethylnormemantine
目录号 : GC69118Fluoroethylnormemantine 是 Memantine 的衍生物,是 N-甲基-D-天冬氨酸 (NMDA) 受体的拮抗剂。[18F]-Fluoroethylnormemantine 可用作正电子发射断层扫描 (PET) 示踪剂。Fluoroethylnormemantine 具有抗遗忘、神经保护、抗抑郁样和减轻恐惧的作用。
Cas No.:1639210-26-6
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Fluoroetlnormemantine, a derivative of Memantine, is an antagonist of the N-metl-D-aspartate (NMDA) receptor. [18F]-Fluoroetlnormemantine can be used as a positron emission tomograp (PET) tracer. Fluoroetlnormemantine exhibits anti-amnesic, neuroprotective, antidepressant-like and fear-attenuating effects[1][2][3].
Fluoroetlnormemantine (0.1-10 mg/kg; a single i.p.) shows anti-amnesic effects on Aβ 25-35-induced learning impairments in mice[1].
Fluoroetlnormemantine (0.1-10 mg/kg; i.p. once daily for 7 days) attenuates Aβ 25-35-induced behavioral deficits, neuroinflammation, oxidative stress, apoptosis, and cell loss in mice[1].
Fluoroetlnormemantine (1-20 mg/kg; a single injection) decreases behavioral despair in the forced swim test (FST) and reduces fear behavior in the cued fear conditioning (FC) and extinction training in rats[2].
Animal Model: | Male Swiss CD-1 mice (7-9 weeks) were injected with Aβ25-35[1] |
Dosage: | 0.1, 0.3, 1, 3, 10 mg/kg |
Administration: | I.p. 30 minutes before the behavioral tests |
Result: | Attenuated Aβ 25-35-induced spontaneous alternation deficit, passive avoidance deficit, and novel object exploration deficit. |
[1]. Couly S, et, al. Anti-Amnesic and Neuroprotective Effects of Fluoroetlnormemantine in a Pharmacological Mouse Model of Alzheimer's Disease. Int J Neuropsychopharmacol. 2021 Feb 15;24(2):142-157.
[2]. Chen BK, et, al. Fluoroetlnormemantine, a novel derivative of memantine, facilitates extinction learning without sensorimotor deficits. Int J Neuropsychopharmacol. 2021 Feb 25;pyab007.
[3]. Chen BK, et, al. Fluoroetlnormemantine, a novel NMDA receptor antagonist, for the prevention and treatment of stress-induced maladaptive behavior. Biological Psychiatry. 2021 May 9.
Cas No. | 1639210-26-6 | SDF | Download SDF |
分子式 | C12H20FN | 分子量 | 197.29 |
溶解度 | DMSO : 100 mg/mL (506.87 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 5.0687 mL | 25.3434 mL | 50.6868 mL |
5 mM | 1.0137 mL | 5.0687 mL | 10.1374 mL |
10 mM | 0.5069 mL | 2.5343 mL | 5.0687 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。